Design Therapeutics (DSGN) Common Equity (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Common Equity data on file, last reported at $218.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 4.33% year-over-year to $218.1 million; the trailing twelve-month figure through Mar 2026 stood at $218.1 million (down 4.33% YoY), and the FY2025 full-year result was $212.5 million, down 12.22% from the prior year.
• Common Equity advanced to $218.1 million in Q1 2026, from $212.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $370.3 million in Q1 2022 to a low of $199.7 million in Q3 2025.
• A 5-year average of $274.4 million and a median of $269.6 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity declined 20.89% in 2025 and retreated 4.33% in 2026, its largest moves.
• Tracing DSGN's Common Equity over 5 years: stood at $327.3 million in 2022, then declined by 15.16% to $277.7 million in 2023, then declined by 12.82% to $242.1 million in 2024, then dropped by 12.22% to $212.5 million in 2025, then grew by 2.61% to $218.1 million in 2026.
• Business Quant data shows DSGN's Common Equity at $218.1 million in Q1 2026, $212.5 million in Q4 2025, and $199.7 million in Q3 2025.